Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 9 - Stockholders' Equity (Details Textual)

Note 9 - Stockholders' Equity (Details Textual) $ / shares in Units, $ in Thousands						1 Months Ended		9 Months Ended
	Aug. 07, 2024 $ / shares shares	Apr. 22, 2024	Jun. 21, 2023 shares	Jun. 22, 2022 shares	Jun. 25, 2021 shares	Nov. 30, 2022 USD ($)	Aug. 31, 2021 USD ($)	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2024 shares	Dec. 31, 2023 $ / shares shares	Dec. 31, 2020 shares
Common Stock, Shares Authorized (in shares)								3,750,000			3,750,000
Common Stock, Shares, Issued (in shares)								1,320,240			1,236,688
Common Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares								$ 0.001			$ 0.001
Preferred Stock, Shares Authorized (in shares)								10,000,000			10,000,000
Preferred Stock, Shares Issued (in shares)								15,618			15,618
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares								$ 0.001			$ 0.001
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)								13.34
Preferred Stock, Shares Outstanding, Ending Balance (in shares)								15,618			15,618
Proceeds from Issuance of Common Stock \| $								$ 0	$ 19,729
Common Stock, Shares, Outstanding (in shares)								1,320,240			1,236,688
Jefferies L L C [Member] \| At the Market Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)								0	24,300,000
Shares Issued, Price Per Share (in dollars per share) \| $ / shares									$ 0.84
Sale of Stock, Authorized Amount \| $						$ 75,000	$ 50,000
Proceeds from Issuance of Common Stock \| $									$ 20,300
Employee Director And Consultant Equity Incentive Plan2020 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)												43,750
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)								333,145				19,746
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)			75,000	37,500	28,125
The 2023 Employee Stock Purchase Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)										9,375
Series A Preferred Stock [Member]
Preferred Stock, Shares Issued (in shares)								85			85
Preferred Stock, Shares Outstanding, Ending Balance (in shares)								85			85
Series B Preferred Stock [Member]
Preferred Stock, Shares Issued (in shares)								4,026			4,026
Preferred Stock, Shares Outstanding, Ending Balance (in shares)								4,026			4,026
Series C Preferred Stock [Member]
Preferred Stock, Shares Issued (in shares)								3,506			3,506
Preferred Stock, Shares Outstanding, Ending Balance (in shares)								3,506			3,506
Series D Preferred Stock [Member]
Preferred Stock, Shares Issued (in shares)								3,000			3,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)								3,000			3,000
Series E Preferred Stock [Member]
Preferred Stock, Shares Issued (in shares)								5,000			5,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)								5,000			5,000
Series F Preferred Stock [Member]
Preferred Stock, Shares Issued (in shares)								1			0
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares	$ 0.01
Preferred Stock, Shares Outstanding, Ending Balance (in shares)								1			0
Preferred Stock, Voting Rights, Number of Votes Per Share	25,000,000
Series F Preferred Stock [Member] \| Board of Directors Chairman [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares	$ 0.001
Stock Issued During Period, Shares, New Issues (in shares)	1
Shares Issued, Price Per Share (in dollars per share) \| $ / shares	$ 1
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		80